PAX3 and neoplasm: In the first 252 tumours published from ZERO, overexpression of FGFR genes was reported in 16 tumours (6.3%), dominated by FGFR4 overexpression in fusion positive RMS (9 tumours), in which FGFR4 overexpression is a known molecular feature and is directly regulated by PAX3-FOXO1 [77].